Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PRA
PRA logo

PRA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Proassurance Corp (PRA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
24.770
1 Day change
0.26%
52 Week Range
24.810
Analysis Updated At
2026/03/20
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Proassurance Corp (PRA) is not a strong buy at this moment for a beginner investor with a long-term focus. While the company's financial performance shows a significant improvement in net income and EPS, the lack of strong trading signals, neutral insider and hedge fund activity, and absence of positive news or catalysts make it less compelling for immediate investment. The technical indicators also do not suggest a clear upward trend, and the options data reflects a bearish sentiment with a high Open Interest Put-Call Ratio. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on this stock is recommended until stronger signals or catalysts emerge.

Technical Analysis

The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 36.081, and moving averages are converging, showing no clear trend. The stock is trading near its pivot point of 24.549, with support at 24.452 and resistance at 24.646. Overall, the technical indicators suggest a lack of strong upward momentum.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
10

Positive Catalysts

  • Net income and EPS have significantly improved YoY in the latest quarter, indicating better profitability.

Neutral/Negative Catalysts

  • Revenue has declined by -5.54% YoY. There is no recent news, no significant insider or hedge fund activity, and no recent congress trading data. Options data shows a bearish sentiment with a high Open Interest Put-Call Ratio.

Financial Performance

In 2025/Q4, revenue dropped by -5.54% YoY to $272.95M. However, net income increased by 106.38% YoY to $33.37M, and EPS rose by 106.45% YoY to 0.64, reflecting improved profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for this stock.

Wall Street analysts forecast PRA stock price to rise
Analyst Rating
0
Wall Street analysts forecast PRA stock price to rise
Buy
Hold
Sell
0
Current: 24.700
sliders
Low
0
Averages
0
High
0
0
Current: 24.700
sliders
Low
0
Averages
0
High
0
Piper Sandler
Paul Newsome
Neutral
maintain
$18 -> $25
AI Analysis
2025-05-08
Reason
Piper Sandler
Paul Newsome
Price Target
$18 -> $25
AI Analysis
2025-05-08
maintain
Neutral
Reason
Piper Sandler analyst Paul Newsome raised the firm's price target on ProAssurance to $25 from $18 and keeps a Neutral rating on the shares. The firm notes the company reported a miss versus PSC and consensus. Underwriting results were worse than expected, but top-line results were higher than Piper expected and premiums in the company's medical malpractice business were stable. Bottom-line results were impacted by non-operating items totaling $12.6M related to its merger with The Doctors Company, the firm adds.
Citizens Capital Markets
Matthew Carletti
Buy
to
Hold
Downgrades
n/a
2025-04-03
Reason
Citizens Capital Markets
Matthew Carletti
Price Target
n/a
2025-04-03
Downgrades
Buy
to
Hold
Reason
Citizens JMP analyst Matthew Carletti downgraded ProAssurance to Market Perform from Outperform without a price target following the announcement that the company will be acquired by The Doctors Company. With the shares currently trading at a 6% discount to Doctors' $25.00 acquisition price, the market is currently fairly discounting the potential outcomes, the analyst tells investors in a research note. Citizens says that while a better, competing offer can never be ruled out, it believes the odds are "quite low."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PRA
Unlock Now

People Also Watch